CYSLTR2 and asthma: In a recent whole blood transcriptomic study of 41 severe asthma patients, in which gene expression levels in peripheral blood were compared at baseline and after four months of treatment with benralizumab [15], significant reductions in the expression of genes associated with eosinophilic inflammatory responses, such as PTGDR2, ALOX15, IL5RA, SMPD3, CLC, HRH4, CYSLTR2, and RAB44, were observed.